On Thursday, Moderna announced that it has injected the first participant in a Phase 1 clinical trial of mRNA-4200 (NCT06880549), an experimental mRNA product that causes the body to produce seven undisclosed tumor proteins following administration.
In other words, the product does not merely introduce tumor proteins into the body—it uses the body itself to manufacture them.
On purpose.
The study raises obvious safety and informed-consent questions about how long the body produces the purportedly encoded tumor proteins, what their long-term biological effects may be, and whether the product or its outputs could be shed from the original recipient onto others through exosomes or extracellular vesicles in excreted bodily fluids.
A 2021 Journal of Extracellular Vesicles study found that cells expressing a target protein can release extracellular vesicles that “carry” that protein, demonstrating that what is produced inside the body can be exported outside the cell in membrane-bound particles.
A separate 2023 Pharmaceutics review explains that exosomes are natural transport vesicles that carry proteins and nucleic acids throughout the body and are present in bodily fluids including blood, saliva, and other secretions—meaning they are not confined to the original cell or even the original location in the body.
You can contact Moderna here and the FDA here.
Hellbound and Down 